The Aging Brain and Neurodegenerative Diseases

Clinics in Geriatric Medicine

Volumn 27, Issue 4, 2011, Pages 629-644

  Duncan, Gary W ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid hypothesis; Apoptosis; Biomarkers; Mitochondrial dysfunction; Neurodegenerative disease; Neuroimaging; Parkinson's disease; Programmed cell death; Proteinopathies; Risk factors for dementia

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPA F 18; AGRICULTURAL CHEMICAL; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; ASCORBIC ACID; BETA CAROTENE; BETA SECRETASE; CONJUGATED ESTROGEN; DONEPEZIL; FOLIC ACID; GALANTAMINE; GAMMA SECRETASE; GINKGO BILOBA EXTRACT; HOMOTAURINE; LEVODOPA; MANGANESE; MEMANTINE; OMEGA 3 FATTY ACID; PARKIN; PLACEBO; RIVASTIGMINE; SEMAGACESTAT; TACRINE; TARENFLURBIL; TAU PROTEIN; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTOPHAGY; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DIETARY INTAKE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL FACTOR; FRUIT; GENE; HEAD INJURY; HEALTH STATUS; HEREDITY; HUMAN; LEWY BODY; LIFESTYLE; MEDITERRANEAN DIET; NERVE CELL NECROSIS; NONHUMAN; NUTRITIONAL STATUS; OXIDATIVE STRESS; PARKIN GENE; PARKINSON DISEASE; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL BEHAVIOR; TRISOMY 21; VEGETABLE;

AGING; BRAIN; HUMANS; MORBIDITY; NEURODEGENERATIVE DISEASES; RISK FACTORS; WORLD HEALTH;

EID: 80555135824     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2011.07.008     Document Type: Review

References (84)

1. Kirkwood T.B.L., Austad S.N. Why do we age?. Nature 2000, 408:233-238.
2. Ropper A., Samuels M. The Neurology of Aging 2005, The McGraw-Hill, New York.
3. Jenkyn L.R., Reeves A.G., Warren T., et al. Neurologic signs in senescence. Arch Neurol 1985, 42:1154-1157.
4. Benassi G., D'Alessandro R., Gallassi R., et al. Neurological examination in subjects over 65 years: an epidemiological survey. Neuroepidemiology 1990, 9:27-38.
5. Ageing and Dementia 1997, Arnold, London. 6th edition. M. Esiri, B. Hyman, K. Beyreuther (Eds.).
6. DeCarli C., Massaro J., Harvey D., et al. Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. Neurobiol Aging 1997, 26:491-510.
7. Burke S.N., Barnes C.A. Neural plasticity in the ageing brain. Nat Rev Neurosci 2006, 7:30-40.
8. Lister J.P., Barnes C.A. Neurobiological changes in the hippocampus during normative aging. Arch Neurol 2009, 66:829-833. 2009.
9. Kirkwood T.B.L. The most pressing problem of our age. BMJ 2003, 326:1297-1299.
10. Bernedetti M.D., Bower J.H., Maraganore D. Smoking, alcohol and coffee consumption preceding Parkinson's disease. Neurology 2000, 55:1350-1358.
11. Bredesen D., Rammohan V., Mehlen P. Cell death in the nervous system. Nature 2006, 443:796-802.
12. Taylor J., Fischbeck K. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
13. Rubinsztein D. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
14. Lin M., Beal M. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
15. Lu T., Pan Y., Kao S., et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004, 429:883-891.
16. Westerlund M., Hoffer B., Olson L. Parkinson's disease: exit toxins, enter genetics. Prog Neurobiol 2010, 90:146-156.
17. Parkinson J. An essay on the shaking palsy 1817, Sherwood, London.
18. Braak H., Ghebremedhin E., Rub U., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
19. Olanow C., Kieburtz K., Schapira A. Why have we failed to achieve neuroprotection in Parkinson's disease?. Ann Neurol 2008, 64:S101-S110.
20. Hely M., Morris J., Reid W., et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems. Mov Disord 2005, 20:190-199.
21. Fearnley J., Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
22. Morrish P., Sawle G., Brooks D. Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995, 59:597-600.
23. Marek K., Seibyl J., Zoghbi S., et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine. Neurology 1996, 46:231-237.
24. Menza M.A., Mark M.H., Burn D.J., et al. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995, 7:176-179.
25. Piccini P., Burn D.J., Ceravolo R., et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999, 45:577-582.
26. Spillantini M., Crowther R., Jakes R., et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease. Proc Natl Acad Sci U S A 1998, 95:6469-6473.
27. Abou-Sleiman P., Muqit M., Wood N. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006, 7:207-219.
28. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
29. Cowan C.M., Chee F., Shepherd D., et al. Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy. Biochem Soc Trans 2010, 38:564-570.
30. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.
31. Rowe C.C., Ng S., Ackermann U., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
32. Edison P., Archer H.A., Hinz R., et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
33. Wolk D.A., Klunk W. Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep 2009, 9:345-352.
34. Wolk D.A., Price J.C., Saxton J.A., et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009, 65:557-568.
35. Jack C.R., Lowe V.J., Weigand S.D., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
36. Green R.C., Schneider L.S., Amato D.A., et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302:2557-2564.
37. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
38. Janus C., Pearson J., McLaurin J., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
39. Morgan D., Diamond D.M., Gottschall P.E., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
40. Gilman S., Koller M., Black R.S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
41. Town T. Alternative Abeta immunotherapy approaches for Alzheimer's disease. CNS Neurol Disord Drug Targets 2009, 8:114-127.
42. Snowdon D.A., Greiner L.H., Mortimer J.A., et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277:813-817.
43. Mohajeri M.H., Leuba G. Prevention of age-associated dementia. Brain Res Bull 2009, 80:315-325.
44. Middleton L.E., Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol 2009, 66:1210-1215.
45. Fillit H., Nash D.T., Rundek T., et al. Cardiovascular risk factors and dementia. Am J Geriatr Pharmacother 2008, 6:100-118.
46. Ott A., Stolk R.P., van Harskamp F., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937.
47. Yaffe K., Blackwell T., Kanaya A.M., et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004, 63:658-663.
48. Luchsinger J.A. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol 2008, 585:119-129.
49. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts?. Alzheimer Dis Assoc Disord 2007, 21:167-171.
50. Launer L.J., Masaki K., Petrovitch H., et al. The association between midlife blood pressure levels and late-life cognitive function: The Honolulu-Asia Aging Study. JAMA 1995, 274:1846-1851.
51. Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005, 4:487-499.
52. Prince M.J., Bird A.S., Blizard R.A., et al. Is the cognitive function of older patients affected by antihypertensive treatment?. Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996, 312:801-805.
53. Muldoon M.F., Ryan C.M., Sereika S.M., et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004, 117:823-829.
54. Morris M.C., Evans D.A., Tangney C.C., et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology 2006, 67:1370-1376.
55. Engelhart M.J., Geerlings M.I., Ruitenberg A., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287:3223-3229.
56. Barberger-Gateau P., Raffaitin C., Letenneur L., et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007, 69:1921-1930.
57. Kang J.H., Ascherio A., Grodstein F. Fruit and vegetable consumption and cognitive decline in aging women. Ann Neurol 2005, 57:713-720.
58. Morris M.C., Evans D.A., Bienias J.L., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003, 60:940-946. 2003.
59. Morris M.C., Beckett L.A., Scherr P.A., et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998, 12:121-126.
60. Masaki K.H., Losonczy K.G., Izmirlian G., et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000, 54:1265-1272.
61. Commenges D., Scotet V., Renaud S., et al. Intake of flavonoids and risk of dementia. Eur J Epidemiol 2000, 16:357-363.
62. Morris M.C., Evans D.A., Bienias J.L., et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002, 287:3230-3237.
63. Foley D.J., White L.R. Dietary intake of antioxidants and risk of Alzheimer disease: food for thought. JAMA 2002, 287:3261-3263.
64. Luchsinger J.A., Tang M.X., Shea S., et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003, 60:203-208.
65. Zandi P.P., Anthony J.C., Khachaturian A.S., et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004, 61:82-88.
66. Dunn J.E., Weintraub S., Stoddard A.M., et al. Serum alpha-tocopherol, concurrent and past vitamin E intake, and mild cognitive impairment. Neurology 2007, 68:670-676.
67. Yaffe K., Clemons T.E., McBee W.L., et al. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 2004, 63:1705-1707.
68. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005, 352:2379-2388.
69. Kang J.H., Cook N., Manson J., et al. A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 2006, 166:2462-2468.
70. Kang J.H., Cook N.R., Manson J.E., et al. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. Circulation 2009, 119:2772-2780.
71. Gu Y., Nieves J.W., Stern Y., et al. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 2010, 67:699-706.
72. Rolland Y., Abellan van Kan G., et al. Physical activity and Alzheimer's disease: from prevention to therapeutic perspectives. J Am Med Dir Assoc 2008, 9:390-405.
73. Rockwood K., Middleton L. Physical activity and the maintenance of cognitive function. Alzheimers Dement 2007, 3(2 Suppl):S38-S44.
74. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20(3 Suppl 2):S69-S74.
75. Carlson M.C., Helms M.J., Steffens D.C., et al. Midlife activity predicts risk of dementia in older male twin pairs. Alzheimers Dement 2008, 4:324-331.
76. Fratiglioni L., Wang H.X. Brain reserve hypothesis in dementia. J Alzheimers Dis 2007, 12:11-22.
77. Acevedo A., Loewenstein D.A. Nonpharmacological cognitive interventions in aging and dementia. J Geriatr Psychiatry Neurol 2007, 20:239-249.
78. Ball K., Berch D.B., Helmers K.F., et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 2002, 288:2271-2281.
79. Neugroschl J., Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai J Med 2010, 77:3-16.
80. Henderson V.W., Paganini-Hill A., Miller B.L., et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000, 54:295-301.
81. Mulnard R.A., Cotman C.W., Kawas C., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000, 283:1007-1015.
82. Craig M.C., Maki P.M., Murphy D.G. The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 2005, 4:190-194.
83. Maki P.M., Gast M.J., Vieweg A.J., et al. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 2007, 69:1322-1330.
84. Daviglus M.L., Bell C.C., Berrettini W., et al. National Institutes of Health State-of-the-Science Conference Statement: preventing alzheimer disease and cognitive decline. Ann Intern Med 2010, 153:176-181.